Introduction
Physiologic | Clinical | Biologic |
---|---|---|
PaO2:FiO2 | Trauma vs. medical | Genomic |
Dead space fraction | Direct vs. indirect | Transcriptomic |
Driving pressure | Focal vs. diffuse | Proteomic |
±Acute kidney injury | Metabolomic |
ARDS Subphenotypes and Prognostic Enrichment
Physiologic Phenotyping for Prognostic Enrichment
Severity | PaO2:FiO2 ratio (mmHg) | Patients (%) | Mortality (%) |
---|---|---|---|
Mild | 201–300 | 22 | 27 |
Moderate | 101–200 | 50 | 32 |
Severe | ≤100 | 28 | 45 |
Clinical Phenotyping for Prognostic Enrichment
Biologic Phenotyping for Prognostic Enrichment
ARDS Subphenotypes and Predictive Enrichment
Physiologic Phenotyping for Predictive Enrichment
Clinical Phenotyping for Predictive Enrichment
Biologic Phenotyping for Predictive Enrichment
Intervention/trial cohort analyzed | Hypoinflammatory subphenotype response | Hyperinflammatory subphenotype response | |||
---|---|---|---|---|---|
Outcome | Intervention | Control | Intervention | Control | |
High vs. low PEEP/ ALVEOLI* [27] | 90-day mortality | 24% high PEEP | 16% low PEEP | 42% high PEEP | 51% low PEEP |
Conservative vs. liberal fluid strategy/ FACCT* [29] | 90-day mortality | 18% conservative fluid strategy | 26% liberal fluid strategy | 50% conservative fluid strategy | 40% liberal fluid strategy |
Simvastatin/ HARP-2 [40] | 28-day survival | No difference | Improved survival with simvastatin (p = 0.008) | ||
Rosuvastatin/SAILS [41] | 90-day mortality | No difference | No difference |